Liquid Biopsy to Inform Targeted Tx of Colorectal Cancer

Video

In this video, Dr. Heinz-Josef Lenz outlines the many advantages that development of liquid biopsy is affording cancer patients.

In this video, Dr. Heinz-Josef Lenz outlines the many advantages that development of liquid biopsy is affording cancer patients.

Recent Videos
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
Alessio Pigazzi, MD, PhD, FACS, FASCRS, provides advice for upcoming surgeons starting out in the colorectal cancer field.
Related Content